Cellulitis
Conditions
Brief summary
Primary: To determine the influence of daptomycin on inflammatory cytokine (IL-1, TNF and IL-6) for the treatment of complicated cellulitis/erysipela compared with alternative treatment (vancomycin or oxacillin). Secondary: To evaluate the clinical outcome of both groups according to levels of the cytokines evaluated.
Interventions
DRUGDaptomycin
daptomycin 4-6mg/kg qd 10 - 14 days
DRUGVancomycin
Vancomycin 1g q12h 10 - 14 days
Sponsors
Hospital Universitario Evangelico de Curitiba
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Eligible patients will be age between 18 and 65 who required hospitalization and parenteral antimicrobial therapy 2. Clinical documentation of cellulitis / erysipela 3. Documentation of a minimal surface area 75 cm2 based on the length and / or width of the redness, swelling and / or induration 4. Documented fever, defined as oral or tympanic temperature greater than or equal to 38 ° C
Exclusion criteria
1. Infections and other minor addition of erysipelas / cellulitis 2. Any recent use of antibacterial drug therapy (systemic or topical antibacterial drugs within 14 days of enrollment) 3. Patients with clinical conditions that alter the interpretation of the primary outcome as patients with neutropenia or compromised immune function, as HIV infection, autoimmune disorders, use of corticosteroids. 4. Patients with known or suspected osteomyelitis. 5. Patients with suspected or confirmed septic arthritis. 6. Patients with complicated skin infections, such as diabetic foot infections. 7. Chronic use of antipyretic drugs (eg, daily use of naproxen). 8\. Less than 18 years of age. 9. pregnancy 10. Patients with mixed infections of Gram-negative or be deleted since the therapy of gram-negative can influence the levels of cytokines. 11\. Patients with renal clearance \<30 mL / min. 12. Patients who are not susceptible to daptomycin or vancomycin. 13. Allergy to study medication.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cytokine levels | AUC will be calculated with multiple time points over a period of 14 days (0, 4, 8, 12 , 16, 24, 48, 72, 96, 120 and 168 hours post-dose) | The results of cytokine levels will be evaluated after completion of antibiotic therapy, when testing will take place in the laboratory. Thus the measurement of cytokines will not be used to evaluate the clinical outcome. |
Countries
Brazil
Outcome results
None listed